A blog about chemistry, drug development, science, and technology
More mergers; now GlaxoSmithKline is getting into the M&A trend and will acquire Domantis for $454 million in cash. It should be noted that Domantis has been around only since 2000.
Everyone knows the big pharma GSK but you may not have heard of Domantis. They make human antibody therapeutics. They have approx. 12 antibody therapeutics in several categories but primarily in the fields of inflammation and oncology.
It will be interesting though since Domantis has a discovery collaboration with Bristol-Myers Squibb since Dec 2005. I’m sure this will change now that GSK is purchasing Domantis.
Here are the press releases:
Domantis
GlaxoSmithKline to acquire Domantis for £230 million - GlaxoSmithKline
This appears to me to be another case of big pharma getting into the biologics and for GSK it looks like a good purchase.
Technorati Tags: pharma M&A, pharmaceutical deals
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 1.407 seconds